August 16, 2023
Surface Oncology, Inc. Investigation
We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Surface Oncology, Inc. (“Surface” or the “Company”) (NASDAQ: SURF), in connection with its proposed acquisition by Coherus BioSciences, Inc. (NASDAQ: CHRS). Under the merger agreement, the Company’s shareholders will receive $5.2831 per share, plus contingent value rights (“CVRs”), subject to certain deductions as set forth in the contingent value rights agreement and payable for a period of ten years following the closing of the transaction.
Join Case →